Search results for "ACUTE MYOCARDIAL-INFARCTION"

showing 5 items of 5 documents

Soluble Platelet Release Factors as Biomarkers for Cardiovascular Disease

2021

Platelets are the main players in thrombotic diseases, where activated platelets not only mediate thrombus formation but also are involved in multiple interactions with vascular cells, inflammatory components, and the coagulation system. Although in vitro reactivity of platelets provides information on the function of circulating platelets, it is not a full reflection of the in vivo activation state, which may be relevant for thrombotic risk assessment in various disease conditions. Therefore, studying release markers of activated platelets in plasma is of interest. While this type of study has been done for decades, there are several new discoveries that highlight the need for a critical a…

0301 basic medicineACUTE MYOCARDIAL-INFARCTIONVON-WILLEBRAND-FACTORDEEP VENOUS THROMBOSISvenous thromboembolismCD40 LIGANDContext (language use)ReviewDiseaseCardiovascular Medicinearterial thrombosis030204 cardiovascular system & hematologyBioinformatics03 medical and health sciences0302 clinical medicineVon Willebrand factorPERIPHERAL ARTERY-DISEASENONVALVULAR ATRIAL-FIBRILLATIONmedicineDiseases of the circulatory (Cardiovascular) systematrial fibrillationPlateletACUTE ISCHEMIC-STROKEMyocardial infarctionPlatelet activationThrombusthrombosisbiologybusiness.industryACUTE CORONARY SYNDROMESbiomarkersmedicine.diseaseThrombosisC-REACTIVE PROTEIN3. Good healthP-SELECTIN LEVELS030104 developmental biologyRC666-701plateletsbiology.proteinCardiology and Cardiovascular MedicinebusinessFrontiers in Cardiovascular Medicine
researchProduct

Geo-economic variations in epidemiology, patterns of care, and outcomes in patients with acute respiratory distress syndrome: insights from the LUNG …

2017

Background Little information is available about the geo-economic variations in demographics, management, and outcomes of patients with acute respiratory distress syndrome (ARDS). We aimed to characterise the effect of these geo-economic variations in patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE). Methods LUNG SAFE was done during 4 consecutive weeks in winter, 2014, in a convenience sample of 459 intensive-care units in 50 countries across six continents. Inclusion criteria were admission to a participating intensive-care unit (including transfers) within the enrolment window and receipt of invasive or non…

MaleARDSdemographyeconomicmedicine.medical_treatmentTerapéuticaair conditioningComorbidityintensive care unitdeveloped country0302 clinical medicineneuromuscular blockingmiddle agedacute myocardial-infarctionmiddle income countryProspective StudiesGeography Medicalcritically-ill patientsadultagedpriority journalrisk factorIncomegeographic-variationDeveloped countryhospitalizationprospective studyHumanPulmonary and Respiratory MedicineDeveloped Countriemedicine.medical_specialtyDeveloping countryArticle/dk/atira/pure/subjectarea/asjc/2700/274003 medical and health sciencesSíndrome respiratorio agudo graveunitsMedicalHumansIntensive care medicineDeveloping CountriesAgedhigh income countryRespiratory Distress Syndrome Adultnoninvasive ventilationAparato respiratoriomedicine.diseasemortalitymajor clinical studyProspective Studiearterial oxygen tension030228 respiratory systemARDSObservational studySociologíahealth care deliverygeographyintensive-careRisk FactorsEpidemiologyProspective cohort studyRespiratory Distress Syndromepartial pressureartificial ventilationSociología médicaMiddle Agedadult respiratory distress syndromeAged; Comorbidity; Delivery of Health Care; Developed Countries; Developing Countries; Europe; Female; Geography Medical; Humans; Income; Intensive Care Units; Male; Middle Aged; Patient Outcome Assessment; Prospective Studies; Respiratory Distress Syndrome Adult; Risk Factors; Pulmonary and Respiratory MedicineEuropeIntensive Care UnitsfemaleincomeFemaleEnfermedadinjurycohort analysigross national incomesurvivalNOmedical geographyDeveloping Countrielength of staymedicinecontrolled studyoutcome assessmentbreast-cancerMechanical ventilationdiseasebusiness.industryDeveloped Countriespatient caredeveloping country030208 emergency & critical care medicinestatistics and numerical data AgedComorbiditywinterACUTE MYOCARDIAL-INFARCTION; CRITICALLY-ILL PATIENTS; GEOGRAPHIC-VARIATION; INTENSIVE-CARE; BREAST-CANCER; MORTALITY; DISEASE; INJURY; UNITS; HOSPITALIZATIONPatient Outcome AssessmentEmergency medicineprone positiontreatment outcomebusinessDelivery of Health Care
researchProduct

Plasma phospholipid transfer protein (PLTP) modulates adaptive immune functions through alternation of T helper cell polarization

2016

International audience; Objective: Plasma phospholipid transfer protein (PLTP) is a key determinant of lipoprotein metabolism, and both animal and human studies converge to indicate that PLTP promotes atherogenesis and its thromboembolic complications. Moreover, it has recently been reported that PLTP modulates inflammation and immune responses. Although earlier studies from our group demonstrated that PLTP can modify macrophage activation, the implication of PLTP in the modulation of T-cell-mediated immune responses has never been investigated and was therefore addressed in the present study. Approach and results: In the present study, we demonstrated that PLTP deficiency in mice has a pro…

0301 basic medicineLymphocyteIpid Transfer ProteinAdaptive ImmunityCardiovascular-DiseaseT-Lymphocytes RegulatoryLipoprotein MetabolismLeukocyte CountPhospholipid transfer proteinPolarizationImmunology and Allergy[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyHypersensitivity DelayedPhospholipid Transfer ProteinsCell PolarityCell DifferentiationT-Lymphocytes Helper-InducerT helper cellFlow CytometryAcquired immune systemCell biologyInfectious Diseasesmedicine.anatomical_structureEndothelial-CellsCytokines[SDV.IMM]Life Sciences [q-bio]/ImmunologyLymphocytemedicine.symptomResearch ArticleDensity-Lipoprotein[SDV.IMM] Life Sciences [q-bio]/ImmunologyHuman Atherosclerotic PlaquesT cellCirculating Interleukin-18ImmunologyT CellAntigen-Presenting CellsInflammationAcute Myocardial-InfarctionGATA3 Transcription FactorBiology03 medical and health sciencesImmune systemmedicineAnimalsAntigen-presenting cellDeficient MiceAlpha-TocopherolMice Inbred C57BL030104 developmental biologyImmunologyVitamin-ET-Box Domain ProteinsBiomarkersSpleen
researchProduct

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countr…

2015

Summary Background The Global Burden of Disease Study 2013 (GBD 2013) aims to bring together all available epidemiological data using a coherent measurement framework, standardised estimation methods, and transparent data sources to enable comparisons of health loss over time and across causes, age–sex groups, and countries. The GBD can be used to generate summary measures such as disability-adjusted life-years (DALYs) and healthy life expectancy (HALE) that make possible comparative assessments of broad epidemiological patterns across countries and time. These summary measures can also be used to quantify the component of variation in epidemiology that is related to sociodemographic develo…

GerontologyMaleCHANGING RELATIONNutrition and DiseaseMESH : Life ExpectancyMESH : AgedECONOMIC-DEVELOPMENTPoison controlMESH: Global HealthGlobal HealthSocioeconomic FactorCommunicable DiseaseMESH : Chronic DiseaseHealth TransitionVoeding en ZiekteQuality-Adjusted Life YearSELF-RATED HEALTHMESH : Socioeconomic FactorsMedicineMESH : FemaleMESH: Mortality Premature2. Zero hungerMESH: Agededucation.field_of_studyMESH: Middle AgedMortality rateMedicine (all)GBD2013 diseases[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieGeneral MedicineMiddle Aged3. Good healthMESH : Wounds and InjuriesEpidemiological transitionMESH: Quality-Adjusted Life YearsMESH: Communicable DiseasesNONCOMMUNICABLE DISEASESFemaleQuality-Adjusted Life YearsMESH: Life ExpectancyMESH: Health TransitionHumanMESH: Socioeconomic FactorsACUTE MYOCARDIAL-INFARCTIONMESH : MaleMORTALITY TRENDSPopulationMESH : Health TransitionCommunicable DiseasesArticleLife ExpectancyEUROPEAN-UNIONSDG 3 - Good Health and Well-beingGeneral & Internal MedicineSYSTEMATIC ANALYSISDisability-adjusted life yearHumansLife ScienceMESH : Middle AgedMortalityeducationPrematureMESH : Mortality PrematureVLAGAgedMESH: Humansbusiness.industryMortality PrematureMESH: Chronic DiseaseMESH : Communicable DiseasesWounds and InjurieMESH : HumansMESH : Quality-Adjusted Life YearsNon-communicable diseaseAged; Chronic Disease; Communicable Diseases; Female; Global Health; Humans; Male; Middle Aged; Mortality Premature; Quality-Adjusted Life Years; Socioeconomic Factors; Wounds and Injuries; Health Transition; Life Expectancy; Medicine (all)medicine.diseaseMESH: MaleLOW SOCIOECONOMIC-STATUSYears of potential life lostSocioeconomic Factors[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMESH: Wounds and InjuriesChronic DiseaseLife expectancyRISK-FACTORSMESH : Global HealthWounds and Injuries[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessMESH: FemaleDemographyLancet
researchProduct

Hospital readmission rates: signal of failure or success?

2013

AbstractHospital readmission rates are increasingly used as signals of hospital performance and a basis for hospital reimbursement. However, their interpretation may be complicated by differential patient survival rates. If patient characteristics are not perfectly observable and hospitals differ in their mortality rates, then hospitals with low mortality rates are likely to have a larger share of un-observably sicker patients at risk of a readmission. Their performance on readmissions will then be underestimated. We examine hospitals’ performance relaxing the assumption of independence between mortality and readmissions implicitly adopted in many empirical applications. We use data from th…

MaleMORTALITY-RATESEconomicsIMPACTSocial SciencesHospital performanceC50Business & EconomicsReadmission ratesmedia_commonAged 80 and overHip fractureOUTCOMESI18Mortality rateHealth PolicyHEALTH CARE SCIENCES & SERVICESHospitalsSurvival RateEngland1117 Public Health And Health ServicesMortality ratesFemaleMedical emergencyHEALTHLife Sciences & BiomedicineSample selectionmedicine.medical_specialtyACUTE MYOCARDIAL-INFARCTIONmedia_common.quotation_subjectBivariate analysisPatient ReadmissionReadmission ratemedicineQUALITYHumansSurvival rate1402 Applied EconomicsSelection (genetic algorithm)AgedQuality of Health CareSelection biasHospital readmissionSAMPLE SELECTIONScience & TechnologyModels Statisticalbusiness.industryHip FracturesPublic Health Environmental and Occupational HealthHIP FRACTUREHEALTH POLICY & SERVICESmedicine.diseaseMortality rateMODELEmergency medicinebusinessRACOSTS
researchProduct